Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?
Summarize this article with:
By Jack Delaney – Apr 18, 2026 at 8:30AM ESTKey PointsJohnson & Johnson exceeded expectations in its Q1 2026 earnings report. Investors weren't blown away by the results. The stock price is down over the last several days. Johnson & Johnson (JNJ 1.49%) has had strong momentum over the last year, with shares trading up more than 52%. After the company's first-quarter 2026 earnings report, however, the response was muted, with the stock price slightly lower following the results' release. With momentum temporarily stalling, here's what to consider before investing in Johnson & Johnson. Image source: Getty Images. Why J&J's stock price is falling despite positive updates For Q1 2026, Johnson & Johnson beat estimates, conservatively boosted its guidance for the year, and showed revenue progress from several drugs. Darzalex, its blood cancer treatment, generated roughly $4 billion in sales, while Tremfya, used to treat inflammatory bowel disease and psoriasis, generated $1.6 billion. ExpandNYSE: JNJJohnson & JohnsonToday's Change(-1.49%) $-3.49Current Price$230.69Key Data PointsMarket Cap$556BDay's Range$229.53 - $235.2652wk Range$146.12 - $251.71Volume4KAvg Vol8.5MGross Margin75.06%Dividend Yield2.25% While positive, the updates weren't enough to offset a concern shareholders may have. Its drug Stelara, which is used to treat autoimmune diseases, saw its patent expire last year, and sales plummeted from $1.6 billion in Q1 2025 to $656 million in Q1 2026 as competition from generic versions increased. Is it worth owning shares on the pullback? In the short term, there likely won't be much news that would move Johnson & Johnson's stock price in either direction. As a long-term investment, Johnson & Johnson has a promising drug pipeline and has offered stability by increasing its dividend payout for 64 consecutive years. It still has to grow into its forward price-to-earnings ratio, which is higher than in recent quarters, but in terms of mixing stability with upside potential, Johnson & Johnson has a lot to offer.Read NextApr 17, 2026 •By Rachel WarrenBest Blue Chip ETFs to Buy in 2026Apr 16, 2026 •By Leo SunThis "Boring" Dividend King Is Quietly Turning Into a Growth MachineApr 16, 2026 •By James Halley3 Healthcare Stocks That Have Held Up in Every Market DownturnApr 15, 2026 •By Jason HallDividend Kings of 2026Apr 15, 2026 •By Matt DiLallo5 Best High Dividend Mutual Funds to Buy in 2026Apr 13, 2026 •By Keith NoonanBest Blue Chip Stocks to Buy in 2026: Should You Invest?About the AuthorJack is a seasoned content strategist with over a decade of experience in financial publishing. He's directed technology, emerging opportunities, and alternative asset publications to deliver actionable insights to investors. He has a B.A. in Communication Studies.TMFJackDelaneyStocks MentionedJohnson & JohnsonNYSE: JNJ$230.69(-1.49%)-$3.49*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.